Targeted siRNA Nanoparticles Induce Neutrophil Cuproptosis to Alleviate Pseudomonas aeruginosa Lung Injury

Study Background and Research Question

Pseudomonas aeruginosa (PA) is a Gram-negative bacterium responsible for severe respiratory infections, particularly in immunocompromised patients. Its capacity for multidrug resistance and immune evasion presents persistent challenges in clinical management, often resulting in high morbidity and mortality rates (reference study). Neutrophils serve as first-line immune effectors in acute bacterial pneumonia, orchestrating both pathogen clearance and inflammation. However, PA manipulates neutrophil cell death mechanisms—including NETosis and pyroptosis—to subvert host defense. A recently recognized form of regulated cell death, cuproptosis, involves copper-dependent mitochondrial dysfunction, but its relevance in neutrophil biology during bacterial infection has remained uncharacterized. This study addresses the question: can targeted modulation of neutrophil cell death pathways, specifically cuproptosis, be leveraged to attenuate PA-induced lung injury?

Key Innovation from the Reference Study

The central innovation of the study lies in the development of a hyaluronic acid (HA)-coated peptide nanoparticle system for targeted delivery of small interfering RNA (siRNA) against Tudor domain-containing protein 9 (TDRD9) in neutrophils. TDRD9 was identified via RNA sequencing as a gene upregulated in pulmonary neutrophils during PA infection. The nanoparticle design exploits HA’s role as an extracellular matrix component with affinity for CD44, a neutrophil surface marker, enabling selective delivery (reference study). Functionally, the platform not only silences TDRD9 but also triggers neutrophil cuproptosis—a cell death program previously unlinked to the antibacterial response—thereby reducing lung injury and bacterial burden. This dual mechanism represents a significant advance in both the targeted modulation of immune cells and the use of matrix-inspired drug delivery vehicles.

Methods and Experimental Design Insights

The study employed a multi-tiered experimental strategy:

• Patient-derived Neutrophil Profiling: Bronchoalveolar lavage fluid neutrophils from 21 patients with PA infection were subjected to RNA sequencing to identify upregulated genes; TDRD9 emerged as a candidate for targeted silencing.
• HA-siRNA Nanoparticle Synthesis: Peptide-based nanoparticles were coated with hyaluronic acid sodium salt, forming a biopolymer shell that enhances targeting and biocompatibility. The use of high molecular weight HA mimics the viscoelastic and cell-adhesive properties of the natural extracellular matrix.
• In Vivo and Ex Vivo Models: The functional effects of TDRD9 knockdown were evaluated through adoptive transfer of TDRD9-silenced neutrophils into neutrophil-depleted mice, as well as administration of HA-si-TDRD9 nanoparticles in PA pneumonia models. Human lung organoids provided additional translational relevance.
• Mechanistic Studies: Downstream signaling was interrogated to reveal that TDRD9 upregulates PD-L1 via interaction with CD80, activating the p38 MAPK pathway—a circuit that restrains cuproptosis and enhances neutrophil survival during infection.

This comprehensive approach allowed the authors to link gene expression changes with functional and mechanistic outcomes in both murine and human systems.

Core Findings and Why They Matter

Key findings from the reference study include:

• TDRD9 expression is significantly elevated in neutrophils isolated from PA-infected lungs, supporting its role as a disease-associated target.
• HA-si-TDRD9 nanoparticles efficiently deliver siRNA to neutrophils in vivo, reduce TDRD9 expression, and enhance cuproptosis, as confirmed by both transcriptomic and functional assays.
• Promotion of neutrophil cuproptosis via TDRD9 silencing leads to reduced pulmonary neutrophil accumulation, attenuation of lung inflammation and edema, and lower bacterial counts in preclinical models.
• Mechanistically, TDRD9 knockdown disrupts the PD-L1/CD80/p38 MAPK axis, lowering PD-L1 levels and facilitating cuproptosis rather than alternative death pathways (e.g., NETosis, pyroptosis).
• In human lung organoids, the nanoparticle system reduces apoptosis and inflammatory cytokine production, mirroring in vivo results and highlighting translational potential.

These findings collectively demonstrate that modulation of a specific neutrophil cell death pathway can be harnessed to limit tissue injury and bacterial proliferation in severe pneumonia. The strategic use of a joint lubrication biopolymer (HA sodium salt) as a delivery vehicle adds an additional layer of clinical relevance, given its established safety and bioactivity as an extracellular matrix component.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on the utility of HA-coated siRNA nanoparticles for immune modulation in infectious disease models:

• The article "siRNA Nanoparticles Target TDRD9 to Alleviate Bacterial Lung Injury" emphasizes the novel mechanism of neutrophil cuproptosis in mitigating PA-induced damage, consistent with the reference study's mechanistic insights.
• "siRNA Nanoparticles Targeting TDRD9 Mitigate P. aeruginosa Lung Injury" further highlights the translational potential of cell death modulation strategies using HA-based delivery systems.
• The review "Hyaluronic Acid Sodium Salt: Translational Leverage in Immune Modulation" discusses the biophysical and signaling properties of HA sodium salt, underlining its suitability as a matrix-mimetic carrier for nucleic acid therapeutics.

Together, these sources reinforce the reference study’s findings and contextualize them within a broader research landscape emphasizing extracellular matrix-inspired delivery and immune modulation.

Limitations and Transferability

While the data are compelling, several limitations warrant consideration:

• Species and model specificity: Most in vivo work was performed in murine systems, and while human lung organoids were utilized, full clinical translation will require further validation in human subjects.
• Nanoparticle pharmacokinetics: The distribution, persistence, and potential off-target effects of HA-siRNA nanoparticles—especially in chronic infection or immunocompromised settings—remain to be systematically evaluated.
• Pathway specificity: Although the study elucidates the PD-L1/CD80/MAPK axis, other compensatory pathways may modulate neutrophil death in different infection contexts or tissue environments.

Nevertheless, the approach’s generalizability to other forms of bacterial pneumonia and acute lung injury is supported by the conserved biology of neutrophil-mediated inflammation and the versatility of HA as a shock absorption polymer and delivery scaffold.

Protocol Parameters

• HA-siRNA nanoparticle preparation: Use high molecular weight hyaluronic acid sodium salt (1,000-1,500 kDa) as a coating material; optimize siRNA:polymer:peptide ratios based on target cell uptake and stability data.
• Neutrophil depletion and adoptive transfer: Deplete endogenous neutrophils using anti-Ly6G antibodies; transfer TDRD9-silenced neutrophils intravenously 24 hours prior to infection challenge.
• siRNA dosing in animal models: Administer HA-si-TDRD9 nanoparticles intravenously at 1–2 mg/kg siRNA equivalent, 4–6 hours prior to PA inoculation; adjust interval and dose for human organoid experiments (nanomolar to micromolar range as supported by product information and literature precedent).
• In vitro validation: Assess TDRD9 knockdown efficiency and cell death markers (e.g., cuproptosis, apoptosis) at 24–48 hours post-treatment using qPCR and immunofluorescence.

Why this cross-domain matters, maturity, and limitations

This work bridges innate immune cell biology with the field of extracellular matrix-inspired nanomedicine. The use of hyaluronic acid sodium salt as both a targeting ligand and PI3K-Akt signaling modulator supports new avenues in immune modulation, though maturity for clinical application will depend on further pharmacodynamic and safety profiling.

Research Support Resources

Researchers interested in replicating or extending these workflows can utilize Hyaluronic acid sodium salt (SKU B8382, APExBIO) as a high-purity, high-molecular-weight matrix component for nanoparticle coatings and cell-based assays. Its established biophysical and signaling roles, as referenced in both the primary and internal studies, provide a robust foundation for translational investigation of siRNA delivery and immune modulation strategies.